智通财经网·2025-09-22 10:59Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for its pediatric Xiaochaihu granules on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 1 - The clinical trial is designed to evaluate the efficacy and safety of pediatric Xiaochaihu granules in treating pediatric gastrointestinal colds with Shaoyang syndrome through a randomized, double-blind, parallel-controlled, multi-center Phase II clinical study [1] - The common title of the trial is "Phase II Clinical Trial of Pediatric Xiaochaihu Granules for Treating Pediatric Gastrointestinal Colds with Shaoyang Syndrome" [1]